transthyretin amyloidosis

Wool heart
Biotech

Don't count out Alnylam's next-gen silencer in ATTR-CM: analysts

Patients' disease stage, transthyretin knockdown levels and trial design have become focal points in debates around silencer-stabilizer combos.
Money present

Royalty pens $425M deal for slice of AstraZeneca ATTR drug sales

Jul 22, 2026 10:01am
AstraZeneca

Hot on Alnylam's heels, AstraZeneca racks up phase 3 ATTR win

Jun 21, 2022 5:41am